3 Reliable Dividend Stocks With Yields Above 5% That You Can Buy With Less Than $100 Right Now

There's no wrong way to put your money to work on Wall Street, but some methods produce more reliable gains than others. If you're looking for a relatively safe and easy way to grow the stream of income you'll have to work with during your retirement years, buying dividend-paying stocks and holding them for long periods is a terrific option.

During the 50-year period that ended in 2023, dividend-paying stocks in the S&P 500 index returned 9.17% annually on average. That's more than double the return produced by their non-dividend-paying cousins. During the same period, the average dividend non-payers in the benchmark index returned just 4.27% annually, according to Ned Davis Research and Hartford funds.

You don't need to be rich to put your money to work for you. At the moment, shares of AT&T (NYSE: T), Hercules Capital (NYSE: HTGC), and Pfizer (NYSE: PFE) offer dividend yields of 5% or better, and you can buy a share of all three with less than $100. Adding them to a portfolio now gives you a good chance to outperform the market while they beef up your passive-income stream.

1. AT&T

AT&T lowered its dividend payout in 2022 to adjust for the sale of its unpredictable media assets. Now that it's strictly a telecommunications business, the cash flows it uses to make dividend payments should be extra reliable. At recent prices, the stock offers a 5.2% dividend yield.

Traditional-wireline subscriptions are still shrinking, but this headwind is easily overcome by demand for services that run on its 5G network and a growing web of fiber-optic cables. In the second quarter, mobility-service revenue rose 3.4% year over year, and this isn't the only operation driving growth.

The three-month period ended June 30 was the 18th consecutive quarter in which AT&T added over 200,000 new fiber-internet subscribers. Late last year, the company also launched a fixed-wireless service for folks who aren't located next to fiber optic cables. As a result, Q2 consumer-broadband sales rose 7% year over year.

At $2.7 billion in Q2, consumer broadband is responsible for less than 10% of total revenue. AT&T is one of just three telecom companies with a nationwide 5G network, so investors can reasonably rely on its consumer-broadband business to drive growth for many years to come.

2. Hercules Capital

Hercules Capital is a business development company (BDC), which means it can avoid income taxes by giving nearly all of its earnings to shareholders as a dividend payment. At recent prices, the stock's regular distribution offers a big 8% yield.

Hercules also offers a supplemental dividend that it set at $0.32 per share this year. If next year's supplemental dividend remains unchanged, investors who buy this stock at recent prices will receive a 9.7% yield.

Most BDCs originate relatively high-interest loans to established mid-sized businesses that already earn money. Hercules Capital takes a riskier approach to financing by engaging start-ups in the life science and technology industries before they have any recurring revenues to report.

In isolation, the bets Hercules makes are extremely risky. The potential payoffs are so large, though, that the company can report strong-earnings growth if just a fraction of its investments succeed.

Hercules has raised or maintained its regular distribution since 2010, and continued movement in the right direction seems likely. In the first half of 2024, the BDC reported $1.07 billion in total-gross funding, which was 28% more than the previous-year period.

3. Pfizer

Sales of Pfizer's COVID-19 vaccine and antiviral treatment broke records regarding its rate of growth and decline. Sales of Comirnaty and Paxlovid shot up to a combined $56.7 billion in 2022. Less than a year and a half later, sales of the same two drugs collapsed to an annualized $1.8 billion.

Don't let its recent ups and downs confuse you. Pfizer is a reliable dividend payer that has raised its payout every year since 2009. At recent prices, it offers a 5.7% yield that will be easier to predict now that sinking sales of its COVID-19 products are responsible for less than 3% of total revenue.

Pfizer's dividend payout is supported by one of the largest catalogs of drugs with patent-protected market exclusivity. In the first half of 2024, a dozen of its products grew sales by a double-digit percentage compared to the previous year period.

One of the investments Pfizer made with its pandemic-related earnings haul was the $43 billion acquisition of cancer drug developer Seagen. The purchase gave Pfizer access to four commercial-stage treatments, including Padcev. In late 2023, Padcev became a chemotherapy-free option for newly diagnosed bladder cancer patients. As such, sales are expected to reach $8 billion annually by 2030.

Padcev is one of several blockbuster drugs that could help Pfizer continue its dividend-raising streak. Adding some shares to a diverse portfolio now seems like the right move.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $21,022!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,329!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $393,839!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” stocks »

*Stock Advisor returns as of October 7, 2024

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.